Medpace Holdings, Inc. $MEDP Stock Holdings Lifted by Giverny Capital Inc.

Giverny Capital Inc. lifted its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 263,320 shares of the company’s stock after buying an additional 1,518 shares during the period. Medpace makes up about 4.9% of Giverny Capital Inc.’s portfolio, making the stock its 7th largest position. Giverny Capital Inc. owned approximately 0.93% of Medpace worth $147,894,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of MEDP. Optiver Holding B.V. purchased a new position in shares of Medpace in the 3rd quarter worth approximately $27,000. Geneos Wealth Management Inc. grew its position in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. purchased a new position in shares of Medpace in the 4th quarter worth approximately $30,000. Elyxium Wealth LLC purchased a new position in shares of Medpace in the 4th quarter worth approximately $30,000. Finally, Quarry LP purchased a new position in shares of Medpace in the 3rd quarter worth approximately $35,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Down 1.6%

MEDP stock opened at $467.34 on Friday. Medpace Holdings, Inc. has a 52 week low of $294.07 and a 52 week high of $628.92. The firm has a 50 day moving average of $456.43 and a 200 day moving average of $504.64. The stock has a market capitalization of $13.35 billion, a PE ratio of 29.37, a price-to-earnings-growth ratio of 2.37 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same period in the previous year, the business posted $3.67 EPS. The business’s quarterly revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts expect that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Insider Activity at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 20.50% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MEDP. Barclays cut their price objective on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research report on Friday, April 24th. Weiss Ratings downgraded shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Royal Bank Of Canada lowered their target price on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Finally, Robert W. Baird lowered their target price on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $467.08.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.